{"classes":[{"categories":[{"measurements":[{"groupId":"OG002","lowerLimit":"1.87","upperLimit":"1.87","value":"1.87"},{"groupId":"OG004","lowerLimit":"1.18","upperLimit":"1.18","value":"1.18"},{"groupId":"OG005","lowerLimit":"1.25","upperLimit":"1.25","value":"1.25"},{"groupId":"OG007","lowerLimit":"0.95","upperLimit":"3.02","value":"2.02"},{"groupId":"OG008","lowerLimit":"1.25","upperLimit":"1.25","value":"1.25"},{"groupId":"OG009","lowerLimit":"0.95","upperLimit":"3.29","value":"1.07"},{"groupId":"OG010","lowerLimit":"0.99","upperLimit":"2.40","value":"1.05"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"6"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"22"},{"groupId":"OG010","value":"23"}],"units":"Participants"}],"description":"TTR was defined as the time from date of first dose, or date of randomization for participants in the Expansion Part B, to time of first response (PR or better).","dispersionType":"Full Range","groups":[{"description":"Participants with RRMM received GEN3014 at a dose of 0.2/0.6 mg/kg by IV infusion in 28-day treatment cycles. Intraparticipant dose escalation was performed in this arm (i.e., dose was escalated from 0.2-0.6 mg/kg).","id":"OG000","title":"RRMM Dose Escalation: GEN3014 0.2/0.6 mg/kg"},{"description":"Participants with RRMM received GEN3014 at a dose of 2 mg/kg by IV infusion in 28-day treatment cycles.","id":"OG001","title":"RRMM Dose Escalation: GEN3014 2 mg/kg"},{"description":"Participants with RRMM received GEN3014 at a dose of 4 mg/kg by IV infusion in 28-day treatment cycles.","id":"OG002","title":"RRMM Dose Escalation: GEN3014 4 mg/kg"},{"description":"Participants with RRMM received GEN3014 at a dose of 8 mg/kg by IV infusion in 28-day treatment cycles.","id":"OG003","title":"RRMM Dose Escalation: GEN3014 8 mg/kg"},{"description":"Participants with RRMM received GEN3014 at a dose of 16 mg/kg by IV infusion in 28-day treatment cycles.","id":"OG004","title":"RRMM Dose Escalation: GEN3014 16 mg/kg"},{"description":"Participants with RRMM received GEN3014 at a dose of 24 mg/kg by IV infusion in 28-day treatment cycles.","id":"OG005","title":"RRMM Dose Escalation: GEN3014 24 mg/kg"},{"description":"Participants with R/R AML received GEN3014 at dose level 1 (low dose) in 28-day treatment cycles.","id":"OG006","title":"R/R AML Dose Escalation: GEN3014 Dose Level 1"},{"description":"Participants with anti-CD38 mAb-naive RRMM received GEN3014 IV infusion at a dose of 16 mg/kg in 28-day cycles during Expansion Part A.","id":"OG007","title":"RRMM Expansion Part A: GEN3014"},{"description":"Participants with R/R DLBCL received GEN3014 IV infusion at a dose of 16 mg/kg in 28-day cycles during Expansion Part A.","id":"OG008","title":"R/R DLBCL Expansion Part A: GEN3014"},{"description":"Participants with anti-CD38 mAb-naive RRMM received daratumumab at a dose of 1,800 mg by subcutaneous (SC) injection in 28-day treatment cycles.","id":"OG009","title":"RRMM Expansion Part B: Daratumumab"},{"description":"Participants with anti-CD38 mAb-naive RRMM received GEN3014 IV infusion at a dose of 16 mg/kg in 28-day treatment cycles.","id":"OG010","title":"RRMM Expansion Part B: GEN3014"}],"paramType":"MEDIAN","populationDescription":"Full Analysis set=all enrolled participants who received at least 1 dose of trial drug (GEN3014 or daratumumab SC). Overall number of participants analyzed=participants evaluable for the outcome measure with a response.","reportingStatus":"POSTED","timeFrame":"Up to approximately 4 years 3 months","title":"Dose Escalation, Expansion Part A and Expansion Part B: Time-to-response (TTR)","type":"SECONDARY","unitOfMeasure":"months"}